Order for xofigo RA223 dichloride injection
Ended Awarded
- Contract number
- 36C26126N0199
- Awardee
-
Bayer Healthcare Pharmaceuticals Inc. UEI V1EVGCK7XES8 Part of Bayer Aktiengesellschaft
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $101,567
Award facts
- Contract value 100% obligated
- $101,567.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Whippany, Hanover, NJ 07981, USA
Award details come from SAM.gov/FPDS.
About this award
Bayer Healthcare Pharmaceuticals Inc., a subsidiary of German-based Bayer AG, was awarded a delivery order on November 6, 2025, for Xofigo (radium Ra 223 dichloride) injection with a ceiling value of $101,567.34. This firm fixed-price delivery order, which is not designated as a small business set-aside, must be completed by January 5, 2026, and will be performed in Whippany, New Jersey. The award was issued under the Federal Supply Schedule (FSS-61-IB) Pharmaceuticals and Drugs contract by Veterans Integrated Service Network 21 (VISN 21), a civilian component of the Department of Veterans Affairs.
This delivery order supports the VA's pharmaceutical supply chain for specialty medications used in veteran healthcare. Xofigo is a radiopharmaceutical used to treat advanced prostate cancer in male patients, representing a critical therapeutic option within the VA's oncology and urology programs. The award draws from Bayer Healthcare's substantial existing contract vehicles with the VA, including an $840 million multiple-award Federal Supply Schedule contract and a $6.8 million Blanket Purchase Agreement specifically covering Xofigo and Adempas medications through October 2026, enabling the agency to rapidly procure essential specialized medications for veteran populations across federal medical facilities.
Quick answers
Who was awarded contract 36C26126N0199?
36C26126N0199 was awarded to Bayer Healthcare Pharmaceuticals Inc. by Veterans Integrated Service Network 21 (Veterans Health Administration) on November 6, 2025.
How much is contract 36C26126N0199 worth?
The government has obligated $101,567 on 36C26126N0199.
Is contract 36C26126N0199 an order under another contract?
Yes. 36C26126N0199 is a delivery order under 36F79720D0237, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26126N0199 competed?
The extent of competition for 36C26126N0199 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award